Anchiano Therapeutics Ltd. is expected to issue 2.4 million shares at $14.55 each Tuesday on the Nasdaq. The company is developing a single biologic candidate to treat bladder and other cancers.
Anchiano has had promising trial results, strong existing investor support of the IPO, and a low IPO valuation, but the early stage of its development may mean the IPO is more appropriate for high risk, long-term life science investors.